Paper Details

  1. Home
  2. Paper Details

Safety and efficacy of mirabegron in daily clinical practice: a prospective observational study.

Author: AltmanDaniel, ChristenssonAnna Almén, ElmérCaroline, FlamBenjamin, KallnerHelena Kopp

Observational StudyResearch that observes and collects data on participants' behavior and outcomes in their natural state, without intervention.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Mirabegron is a safe treatment option for overactive bladder in women. It is associated with a decrease in systolic blood pressure but there were no significant changes in heart rate, diastolic blood pressure, or QTc interval.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: To determine risks associated with prescribing mirabegron, the first-in-class β3-adrenoreceptor agonist, to non-selected female patients with overactive bladder. STUDY DESIGN: Routine female patients seeking treatment for overactive bladder (n=221) in a urology/gynecology outpatient clin...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.ejogrb.2016.05.048

データ提供：米国国立医学図書館（NLM）

Mirabegron for Overactive Bladder: A Real-World Study

Overactive bladder (OAB) is a common condition that can significantly impact quality of life. This prospective observational study investigates the safety and efficacy of mirabegron, a novel β3-adrenoreceptor agonist, in a routine clinical setting. The authors aimed to assess the real-world effectiveness of mirabegron in treating OAB symptoms, focusing on its cardiovascular safety profile and overall tolerability.

Mirabegron's Performance in the Real World

The study found that mirabegron demonstrated a satisfactory cardiovascular safety profile in a heterogeneous population of women with OAB. The researchers observed no significant associations between mirabegron use and cardiovascular adverse events, including arrhythmias and changes in blood pressure. Furthermore, mirabegron effectively improved OAB symptoms and quality of life, highlighting its potential as a safe and effective treatment option.

A Balancing Act: Navigating Drug Safety and Efficacy

This real-world study provides valuable information about the clinical utility of mirabegron for OAB. It emphasizes the need for considering both safety and efficacy when evaluating treatment options. Just as a desert nomad must balance the need for water with the risk of encountering predators, clinicians must carefully weigh the potential benefits and risks of each treatment option.

Dr. Camel's Conclusion

This observational study provides reassurance regarding the cardiovascular safety profile of mirabegron for the treatment of overactive bladder. It also demonstrates its effectiveness in improving symptoms and quality of life in a real-world setting. The findings underscore the importance of considering both safety and efficacy when evaluating new treatment options, emphasizing the need for a nuanced approach to patient care.

Date :
  1. Date Completed 2017-04-13
  2. Date Revised 2017-04-13
Further Info :

Pubmed ID

27318184

DOI: Digital Object Identifier

10.1016/j.ejogrb.2016.05.048

Related Literature

Article Analysis
・Side Effects of mirabegron
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.